Clinical Trial

Exchangeable and Relative Exchangeable Copper as an Alternative to 24-Hour Urinary Copper in Wilson's Disease Monitoring

Completed
View on ClinicalTrials.gov →
Summary
Serum exchangeable copper (EC) and relative exchangeable copper (REC) are blood tests developed to improve the assessment of copper levels in patients with Wilson's disease. EC measures the fraction of copper in the blood that is not bound to ceruloplasmin and reflects copper accumulation in the body. REC represents the proportion of this exchangeable copper relative to total serum copper. Previous studies have shown that EC and REC are more accurate than traditional copper tests for diagnosing Wilson's disease. This study aimed to evaluate the relationship between EC/REC and routine copper measurements in patients with Wilson's disease during follow-up, to assess their potential value in disease monitoring.
Trial Details
NCT Number NCT07462026
Lead Sponsor Hacettepe University
Conditions Wilson's Disease
Enrollment 81 participants
Start Date 2021-01-31
Primary Completion 2021-09-05 (estimated)
Study Completion 2021-09-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-10